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Fosfomycin in vitro resistance of Escherichia coli from the community
It is common practice in many places all over Brazil to use fosfomycin in the treatment of uncomplicated urinary tract infections, although resistance profi le is not currently well-known in our country.
We would like to report the fi ndings of in vitro activity of fosfomycin against 240 nonduplicate consecutive E. coli strains isolated from community urinary samples (> 10 5 CFU/ mL in October 2009) from Curitiba (Paraná, Brazil). Susceptibility test were performed according to CLSI, using disk diffusion with 200 mg of fosfomycin disk with zone diameter breakpoint as recommended by CLSI. 1 Clinical data were not evaluated and no statistical analysis was performed, considering the descriptive nature of the study.
The susceptibility of E. coli to fosfomycin was 98.8% and to other antibiotics ranged from 66.3 -99.2% as follows: sulfamethoxazole (66.3%), nalidixic acid (78.3%), quinolones (81.3%, including ciprofl oxacin, levofl oxacin and norfl oxacin), amoxicillin/clavulanic acid (88.7%), nitrofurantoin (99.2%) and ceftriaxone (99.2%).
In the present study E. coli isolates from patients with urinary infection were highly susceptible to fosfomycin. These data suggest that fosfomycin may be a good alternative for fi rst line antimicrobial treatment of uncomplicated low urinary tract infections. 2 It is well-known that variations in bacterial resistance patterns for Escherichia coli occur amongst different populations. 3 It is mandatory for clinicians to be constantly aware of the local bacterial resistance profi les in order to update empirical antimicrobial regimens. Fosfomycin also seems to be a reasonable option for bacteria other than E. coli, such as Enterococcus. 4 In our area, fosfomycin is a good option, but this cannot be extrapolated to other regions of the country. On going surveillance studies are needed in the country.
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